Format

Send to

Choose Destination
FEBS Lett. 2009 May 6;583(9):1409-14. doi: 10.1016/j.febslet.2009.04.011. Epub 2009 Apr 18.

HSP70 protects BCL2L12 and BCL2L12A from N-terminal ubiquitination-mediated proteasomal degradation.

Author information

1
Gene Research Center, Shanghai Medical College, Fudan University, Box 103, No. 138 Yi Xue Yuan Road, Shanghai 200032, PR China.

Abstract

BCL2L12 has been found to be associated with favorable prognosis in breast cancer patients while correlated with tumorigenesis of glioblastoma and colon cancer. Here, we report that BCL2L12 and its transcript variant BCL2L12A are degraded through ubiquitin-proteasome system (UPS). Interestingly, the ubiquitinations and degradations of BCL2L12 and BCL2L12A are independent of the internal lysine residues but the first N-terminal residues. In addition, HSP70 was identified to interact with BCL2L12 and BCL2L12A and protected them from ubiquitinations and degradations in mammalian cells. In summary, HSP70 protects BCL2L12 and BCL2L12A from N-terminal ubiquitination-mediated proteasomal degradation.

PMID:
19376117
DOI:
10.1016/j.febslet.2009.04.011
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center